Speaking at a press conference in Beijing, Chinese health officials said the country was expected to produce 610 million doses of COVID-19 vaccine by the end of this year and at least 1 billion doses per year from 2021.

According to an official at the Ministry of Science and Technology of China, 11 types of COVID-19 vaccines developed by the country are currently under clinical trials, of which four are in the process of phase 3 testing and finalized. positive results. The test results showed that the vaccine was safe and did not cause side effects. In addition, China is also studying 59 other vaccines.

* On the same day of September 25, the pharmaceutical firm Endo based in Ireland said it was producing the COVID-19 vaccine developed by the US Novavax Group. This announcement by Endo pushed up its share price 10% prior to the same day trading.

Accordingly, Endo signed an agreement with Novavax to produce vaccine NVX-CoV2373 in room COVID-19. The first batch of vaccine will be used by Novavax in the phase 3 clinical trial conducted in the US. Currently the terms of this deal have not been disclosed. 

The day before, Novavax started a phase 3 clinical trial of the NVX-CoV2373 vaccine in the UK.

NVX-CoV2373 is still in the second testing phase after it has shown that vaccines can produce large amounts of antibodies.